Mixed Agonist/Antagonist Opioid Analgesics has 6 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Hydromorphone Hydrochloride, Morphine Sulfate, Oxycodone Hydrochloride. Patients taking Mixed Agonist/Antagonist Opioid Analgesics should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 4
- Moderate
- 2
Major (4)
- Mixed Agonist/Antagonist Opioid Analgesics + Hydromorphone Hydrochloride— Concomitant use may reduce analgesic effect and/or precipitate withdrawal symptoms. Avoid concomitant use.
- Mixed Agonist/Antagonist Opioid Analgesics + Morphine Sulfate— May reduce analgesic effect of morphine and/or precipitate withdrawal symptoms. Concomitant use should be avoided.
- Mixed Agonist/Antagonist Opioid Analgesics + Oxycodone Hydrochloride— May reduce analgesic effect of oxycodone or precipitate withdrawal symptoms. Avoid concomitant use.
- Mixed Agonist/Antagonist Opioid Analgesics + Oxymorphone Hydrochloride— May reduce analgesic effect of oxymorphone or precipitate withdrawal symptoms.
Moderate (2)
- Mixed Agonist/Antagonist Opioid Analgesics + Remifentanil Hydrochloride— May reduce analgesic effect and/or precipitate withdrawal symptoms. Careful observation during treatment initiation and …
- Mixed Agonist/Antagonist Opioid Analgesics + Tapentadol Hydrochloride— May reduce the analgesic effect of tapentadol and/or precipitate withdrawal symptoms.